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After an ectopic pregnancy (EP) fertility decreases, mostly due to tubal factor. Hysterosalpingography (HSG) is the most cost-
eﬀective tool for tubal patency assessment. Objective. To evaluate the usefulness of a HSG after a medical treatment for an EP,
in order to counsel women on the most appropriate way to conceive future pregnancies. Methods. Between 1998 and 2008, 144
patients were submitted to medical treatment for an EP and performed HSG 3 months after the event. Results. 72.2% of normal
HSG, 18.8% with unilateral obstruction, 6.3% tubal patency with defect, and 2.8% bilateral obstruction. Conclusion. Routine HSG
following medical treatment for an EP does not seem necessary, as it does not change the initial management in 97.2% of the cases,
but might be considered in selected risk cases, permitting timely referral of patients to in vitro fertilization.
1.Introduction
Ectopic pregnancy (EP) is deﬁned as the abnormal implan-
tation of the blastocyst outside the uterine endometrium.
It aﬀects 2% of all pregnancies and is associated with
signiﬁcant maternal morbid mortality, being the main cause
of maternal death during the ﬁrst trimester of gestation
[1]. The most common site of implantation is the Fallopian
tube (in the ﬁmbrial end, ampullary section, or isthmus)
but can also be interstitial, ovarian, abdominal and cer-
vical, or on the site of a previous cesarean section scar
[2].
Females with abnormal Fallopian tubes are at increased
risk of developing an EP [3]. Thus, the risk factors for devel-
oping EP include pelvic inﬂammatory disease (PID), history
of EP, infertility, history of pelvic or abdominal surgery,
endometriosis, sexually transmitted diseases, previous tubal
surgery(namelytubalsterilization),smoking,oldermaternal
age, and in uterus exposure to diethylstilbestrol.
Some of these conditions result in scar tissue at the
Fallopian tubes and may thus prevent the fertilized egg to
reach the uterine cavity.
Despite the fact that the treatment is classically surgical,
early diagnosis allows the implementation of a medical treat-
ment [4], thus avoiding the surgery-associated morbidity
and maintaining the patient’s anatomy.
Several medical treatments have been used such as
prostaglandins, dactinomycin, etoposide, hyperosmolar glu-
cose, anti-hCG antibodies, potassium chloride, or mifepris-
tone. However, the treatment with methotrexate (MTX) has
shown better results and is presently considered the ﬁrst
option for medical therapy [5].
MTX is chemotherapeutic drug, antagonist of folic acid
and acts as an antimetabolite, by combining with the enzyme
tetrahydrofolate reductase. It inhibits the synthesis of puric
and pyrimidic bases, essential for the formation of DNA
and RNA. Its action is exerted on cells with fast replication,
including the trophoblast [6].2 Obstetrics and Gynecology International
Themedicaltreatmentwithmethotrexatemaybeapplied
systemically (intramuscular administration of MTX) or by
direct injection inside the gestational sac, whether guided by
ultrasound or by a laparoscopic approach.
MTX destroys cells in fast replication (in this case the
trophoblast). However, this process may result in residual
lesion to the Fallopian tube. Fertility after a conservative
treatment for an EP can be attested indirectly through a
hysterosalpingography (HSG) or directly by diagnosing a
new gestation [7].
HSG is the radiographic evaluation of the uterine cavity
and fallopian tubes after the administration of a radio-
opaque medium through the cervical canal. The ﬁrst HSG
was performed in 1910 and was considered to be the ﬁrst
special radiologic procedure. A properly performedHSG can
detect the contour of the uterine cavity and the width of
the cervical canal. Further contrast medium injection will
outline the cornua isthmic and ampullary portions of the
tubes and will show the degree of spillage.
It has a sensibility of 0.65 (CI 95% 0.5–0.78) and a
speciﬁcity of 0.83 (CI 95% 0.77–0.88) [8]. Thus, given the
high speciﬁcity of the HSG, in case of diagnosis of tubal
obstruction, there is a high probability that it really exists,
while the observation of tubal permeability shown by the
exam does not exclude tubal pathology, since it does not
assess its function.
On the other side, the HSG has a high reproducibility
both intra- and interobservers, mainly in cases of proximal
obstructions [9].
In addition, HSG is a safe and inexpensive procedure
[10], being the most cost-eﬀective method in the study of the
Fallopian tubes [11].
Evidence shows that fertility decreases following an EP
[12]. Future fertility in these patients is dependent on
several factors, including age, history of infertility, history
of previous EP, tubal rupture, and contralateral tubal lesion
[13]. Thus, it seems reasonable to assess tubal permeability
following a medical treatment of an EP in those women who
are willing to have future progeny.
The aim of this study is to assess the usefulness of
HSG following medical treatment of EP in order to counsel
patients willing to have future gestations about the most
appropriate method of conception. The secondary aims of
the study are to evaluate the clinical eﬀectiveness of the
diﬀerent modalities of treatment and fertility rates following
a medical treatment of EP.
2.MaterialsandMethods
2.1. Study Design and Participants. The Ethics Committee of
the Corporaci´ o Sanit` aria Parc Taul´ ı approved this study. An
observational retrospective study was performed, including
all women submitted to HSG following conservative man-
agement of an EP at the Institution between 1998 and 2008.
2.2. Treatments for Ectopic Pregnancy. Indications for con-
servative treatment with methotrexate (MTX) were [14]
hemodynamic stability without evidence of active bleeding
or hemoperitoneum, willingness of having future progeny,
possibility of followup, absence of contraindications for
MTX, gestational sac with maximum diameter of 4cm, and
no embryonic cardiac motion.
The maximum initial beta human chorionic gonadot-
rophin (β-HCG) serum level considered for intramuscular
systemic treatment was 3000mUI/mL and 10000mUI/mL
for intrasacular injection. Additionally, in case of intrasac-
ular ultrasonographically guided treatment, gestational sac
should be accessible to ultrasonography guidance.
Contraindications for treatment with MTX included
[5] intrauterine gestation, immunodeﬁciency, moderate to
severe anemia, leucopenia or thrombocytopenia, known
MTX sensitivity, acute respiratory disease, active peptic ulcer
disease, major hepatic or renal impairment, and breast-
feeding.
MTX was administered as a standard dose of 50mg for
intrasacular injection and 50mg/m2 of body surface area
(BSA) for systemic intramuscular treatment. The formula
used for assessment of BSA in square meters was: [height
(cm) + weight (Kg) − 60]/100.
2.3. Hysterosalpingography. A pregnancy test was ruled out
before the HSG and proﬁlaxis with doxycycline was rec-
ommended to all patients. Because patients may experience
cramping during the HSG, women were advised to take
a nonsteroidal anti-inﬂammatory drug one hour prior to
the procedure. There were two contraindications for HSG:
pregnancy and active pelvic infection.
The procedure was performed with a sterile technique,
with a single-tooth tenaculum applied to align the cervical
canal and uterine cavity. Approximately 10mL of water-
soluble contrast medium was injected through a cannula.
Fluoroscopic examination was performed during the injec-
tion with patient repositioning as necessary.
HSG was performed in immediate postmenstrual phase,
3 months after the medical treatment for the EP, when
the image of an extraovarian adnexal mass disappears at
transvaginal ultrasound.
The examination was performed, read, and interpreted
by a radiologist. The radiographic ﬁndings were scored as:
normal, unilateral patency, patency but with defects (namely
a no obstructive hydrosalpinx), and bilateral obstruction.
2.4. Data Collection. Data were gathered concerning patient
demographic characteristics (age, parity, risk factors for
EP) and details of the occurrence (laterality of EP, type
of treatment, outcome of treatment, and HSG ﬁndings).
In March 2009, a phone query was performed, and data
concerninglatergestationsandmodeofconception,whether
spontaneous or through medically assisted reproduction,
were collected.
2.5. Statistical Analysis. All used tests were bilateral. The
level of statistical signiﬁcance was considered for P<
0.05. Statistical analysis was performed using the software
PASW Statistics version 18.0.0 (SPSS Inc., IBM Corporation,
Chicago. Il, USA).
Quantitative variables were described through aver-
ages and standard deviations. Categorical variables were
described by frequencies.Obstetrics and Gynecology International 3
Distribution of probabilities for quantitative variables
was tested for normality by Kolmogorov-Smirnov test.
Diﬀerences between groups were analyzed by Student’s t-test
fornormalquantitativevariables.ThenonparametricMann-
WhitneyU testwasusedincaseofnonnormality;diﬀerences
between proportions were analyzed with the Pearson’s chi-
square test or Fischer’s exact test.
3. Results
3.1. Patients’ Characteristics and Treatment Eﬀectiveness.
HSG was performed in 144 women, following medical
treatment of EP. Patients’ average age was 30.27 years (range
16–40). Risk factors for EP were absent in 42, 76% of the
population. Intramuscular treatment was performed in 84
cases (58.3%) and intrasacular in 60 (41.7%). The initial
treatment was eﬀective in 91% of the situations. Table 1
shows the eﬀectiveness of the diﬀerent types of treatment.
We failed to reveal statistical signiﬁcant diﬀerences between
treatment modality (P = 0.562).
Initial treatment failed in 13 cases (9%), 6 following
intramuscular MTX, 2 following ultrasonography-guided
MTX intrasacular injection, and 5 after laparoscopic MTX
intrasacular injection. A second treatment was oﬀered
to these 13 patients: 10 were treated with intramuscular
MTX and 3 with salpingectomy. One intramuscular MTX
treatment failed and was managed by salpingectomy. Thus,
only 4 out of 144 patients required ablative surgery, with the
remaining being successfully managed by medical treatment.
3.2. Findings on Hysterosalpingography and Subsequent Fer-
tility. Among the 144 HSG performed in women submitted
to medical treatment for EP, 104 (72.2%) were normal, 27
(18.8%) displayed unilateral obstruction, 4 (2.8%) bilateral
obstruction, and 9 (6.3%) tubal patency, but with defect.
Table 2 shows the ﬁndings on HSG according to the diﬀerent
types of treatment. Signiﬁcant diﬀerences on HSG ﬁndings
were depending on the therapeutic modality (P = 0.025),
being the intramuscular treatment the one with a greater
number of normal HSG. Similar ﬁndings were observed
in the group of patients that required a second treatment
(P = 0.044).
No signiﬁcant diﬀerences were found in the HSG ﬁnd-
ings when comparing patients submitted to a single or an
additional treatment (P = 0.124).
23 patients (15.97%) were lost to follow up. Among
the remaining 121 who received medical treatment for EP,
83.5% accomplished a subsequent gestation, 78.5% without
medically assisted reproduction. Moreover, as shown in
Table 3, the type of treatment did not signiﬁcantly aﬀect the
pregnancy rate (P = 0.127). No diﬀerences were found in
the pregnancy rate in the group of patients submitted to an
additional treatment (P = 0.4).
In face of an unchanged HSG, 90.6% of the women
achieved a later gestation. However, ﬁndings of unilateral
obstruction resulted in a decrease of the pregnancy rate to
76% and to 62.5% in case of tubal patency with alteration
(Table 4). These diﬀerences were statistically signiﬁcant
(P<0.0005).
All patients in the group of bilateral obstruction (3 pa-
tients) failed to attain a later gestation, with two presently
in process of in vitro fertilization. Among them, one had
previous history of an additional EP, other had a cornual
pregnancy following several myomectomies treated with
ultrasonography-guidedintrasacularMTXinjection,andthe
otheratorpidevolution.Subsequentspontaneouspregnancy
rate was also signiﬁcantly aﬀected by the HSG ﬁndings
(P = 0.004).
4. Discussion
Our data show that ﬁndings on HSG were diﬀerent accord-
ing to the therapeutic approach, with the intramuscular
treatmentcarryinganincreasedratioofnormalexams,when
compared to the intrasacular injection. Two reasons could
explain these ﬁndings: the inclusion criteria for intrasacular
treatment allow higher initial levels of β-HCG. The increase
in β-HCG levels is related to an enhancement in tubal
obstruction risk, probably because in patients with high
levels of β-HCG there is more invasion of the trophoblast
tissue at the serosa of the tube, which increases the dam-
age [15]. Additionally, the intrasacular treatment requires
direct tubal puncture, possibly injuring the Fallopian tube
with consequent increased scarring and additional peritubal
peritoneal adhesions.
Nevertheless, it must be highlighted that data is lacking
on the basis of the tubal defects identiﬁed after an EP,
whether they were a consequence of the treatment or were
already present and were thus the cause of an abnormal
implantation.
The subsequent pregnancy rate was also signiﬁcantly
inﬂuenced by the ﬁndings on the HSG, being higher in
the patients with normal HSG. Moreover, an increased
proportion of spontaneous gestations was observed in these
subjects.Moletal.reportedfecundityrateratiosofone-sided
and two-sided abnormalities detected with HSG of 0.93 and
0.35, respectively [16].
Despite the obvious disadvantages of being a retrospec-
tive study, in light of the present results, it seems reasonable
to consider that performing a HSG following medical
treatment of an EP could provide prognostic information
regarding future attempts to accomplish gestation.
Conversely, in 97.2% of the patients the HSG ﬁndings
would be unlikely to aﬀect the initial conduct that would
probably be expectant, including the group of fertile women
exhibiting unilateral tubal obstruction or tubal patency with
alteration. Furthermore, only the 2.8% of women diagnosed
bilateral tubal obstruction would probably beneﬁt from
HSG, being recommended in vitro fertilization. As previ-
ously stated, these patients presented history of previous
tubal pathology or diﬃcult management of EP. Therefore,
it could be considered the beneﬁt of performing HSG in
such patients, in whom a prompt diagnosis of bilateral
obstruction would result in adequate counseling towards in
vitro fertilization, devoid of delay.
The medical treatment with MTX for EP is eﬀective
and safe: 91% success on a ﬁrst treatment (considering
both intramuscular and intrasacular administration) with-
out any relevant complication. The Practice Committee of4 Obstetrics and Gynecology International
Table 1: Eﬀectiveness of the diﬀerent medical treatment modalities. Results are expressed as frequencies and percentage (P = 0.562).
Success of treatment
Yes No
Treatment
Intramuscular Total 78 6
% 92.9% 7.1%
Ultrasonography-guided intrasacular injection Total 20 2
% 90.9% 9.1%
Laparoscopic intrasacular injection Total 33 5
% 86.8% 13.2%
Total Total 131 13
% 91% 9%
Table 2: Findings on hysterosalpingography according to initial treatment modality for ectopic pregnancy. Results are expressed as
frequencies and percentage (P = 0.025).
Findings on hysterosalpingography
Normal Unilateral patency Bilateral obstruction Patency with alteration
Treatment
Intramuscular Total 69 11 1 3
% 82.1% 13.1% 1.2% 3.6%
Ultrasonography-guided
intrasacular injection
Total 14 52 1
% 63.6% 22.7% 9.1% 4.5%
Laparoscopic intrasacular
injection
Total 21 11 1 5
% 55.3% 28.9% 2.6% 13.2%
Total Total 104 27 4 9
% 72.2% 18.8% 2.8% 6.3%
Table 3: Pregnancy rate according to treatment administered for ectopic pregnancy. Results are expressed as frequencies and percentage
(P = 0.127).
Subsequent pregnancy
Yes No
Treatment
Intramuscular Total 62 8
% 88.6% 11.4%
Ultrasonography-guided intrasacular injection Total 14 6
% 70% 30%
Laparoscopic intrasacular injection Total 25 6
% 80.6% 19.4%
Total Total 20 101
% 16.5% 83.5%
Table 4: Accomplishment of subsequent pregnancy according to the ﬁndings on hysterosalpingography (HSG). Results are expressed as
frequencies and percentage (P<0.0005).
Subsequent pregnancy
Yes No
Findings on HSG
Normal Total 77 8
% 90.6% 9.4%
Unilateral patency Total 19 6
% 76.0% 24.0%
Bilateral obstruction Total 0 3
% 0% 100%
Patency with alteration Total 5 3
% 62.5% 37.5%
Total Total 20 101
% 16.5% 83.5%Obstetrics and Gynecology International 5
the American Society for Reproductive Medicine published
in 2008 that MTX treatment was successful in 78%–96% of
selected patients [17]. It seems clear that in order to achieve
comparable good results, compliance with patient selection
criteria is essential.
Fertility following medical treatmentwas noticeably high
(83.5%),with78.5%spontaneouspregnancies.Nevertheless,
it must be considered that not all patients sought pregnancy
after treatment; thus, fertility rates could even achieve
higher levels if only women seeking further gestation were
considered or if no limitations existed on the access to
medically assisted reproduction
5. Conclusions
Findings on HSG carry a prognostic value when considering
future fertility, following medical treatment of EP. However,
initial management is aﬀected only in 2.8% of the women.
Further studies should be undertaken in order to conﬁrm
the present results that suggest that routine HSG following
medical treatment for an EP does not seem necessary but
might be considered in selected risk cases, permitting timely
referral of patients to in vitro fertilization
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